SCHEMBL5564423

SCHEMBL5564423

COc1cc(C)ccc1Nc1ncnc2c(C)cccc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.56
KDR P35968 1/20 0.56
HPGD P15428 3/20 0.52
ALDH1A1 P00352 2/20 0.52
MAPK1 P28482 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
EGFR P00533 2/20 0.50
KDM4E B2RXH2 3/20 0.47
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
LMNA P02545 1/20 0.47
MAPT P10636 2/20 0.46
POLB P06746 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
NPC1 O15118 1/20 0.46
NCOA1 Q15788 1/20 0.46
NCOA3 Q9Y6Q9 1/20 0.46
TSHR P16473 1/20 0.45
HSD17B10 Q99714 1/20 0.45
RET P07949 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5569131 0.79 RET (0.48) HTTKDRHPGDALDH1A1EGFR
SCHEMBL5564595 0.79 ABCG2 (0.67) HTTKDRHPGDALDH1A1MAPK1
SCHEMBL5569119 0.73 TP53 (0.50) KDREGFRMAPTPOLBL3MBTL1
SCHEMBL5569127 0.72 MEN1 (0.48) HTTHPGDALDH1A1MAPK1SMN1; SMN2
SCHEMBL27109251 0.72 KDR (1.00) HTTKDREGFRRETKIF5B
SCHEMBL5569470 0.71 EGFR (0.58) HTTKDRHPGDALDH1A1MAPK1
SCHEMBL5564904 0.71 KDR (0.42) KDREGFRMAPTRETKIF5B
SCHEMBL5565218 0.70 BRD4 (0.50) KDREGFRKMT2AMEN1POLB
SCHEMBL15179542 0.70 EGFR (0.52) HTTKDREGFRRETKIF5B
SCHEMBL19998628 0.69 EGFR (0.48) HTTKDREGFRKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US claimed
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US disclosed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP disclosed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections IRF3, PML, TPMT HTT 2700/4885KDR 2712/4885HPGD 1454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.